The purpose of this study was to determine whether thrombospondin (TSP)-1 promotes macrophage activity and disease progression in dysferlinopathy. First, we found that levels of TSP-1 are elevated in blood of non-ambulant dysferlinopathy patients compared with ambulant patients and healthy controls, supporting the idea that TSP-1 levels are correlated with disease progression. We then crossed dysferlinopathic BlaJ mice with TSP-1 knockout mice and assessed disease progression longitudinally with magnetic resonance imaging (MRI). In these mice, deletion of TSP-1 ameliorated loss in volume and mass of the moderately affected gluteal muscle but not of the severely affected psoas muscle. T2 MRI parameters revealed that loss of TSP-1 modestly inhibited inflammation only in gluteal muscle of male mice. Histological assessment indicated that deletion of TSP-1 reduced inflammatory cell infiltration of muscle fibers, but only early in disease progression. In addition, flow cytometry analysis revealed that, in males, TSP-1 knockout reduced macrophage infiltration and phagocytic activity, which is consistent with TSP-1-enhanced phagocytosis and pro-inflammatory cytokine induction in cultured macrophages. In summary, TSP-1 appears to play an accessory role in modulating Mp activity in BlaJ mice in a gender, age and muscle-dependent manner, but is unlikely a primary driver of disease progression of dysferlinopathy.
Introduction
Dysferlinopathies, including limb-girdle muscular dystrophy type 2B and Miyoshi myopathy, are caused by mutations in the dysferlin gene that result in a late-onset, severe myopathy (1) (2) (3) . Dysferlin, which is expressed in skeletal and cardiac muscle cells as well as monocytes (Mo) and macrophages (Mp) (4, 5) , is known to play roles in membrane trafficking, fusion and repair (6, 7) . However, the mechanisms that contribute to disease onset and progression remain to be elucidated.
Dysferlinopathy is also associated with an exuberant, Mpdominated inflammatory response, which is thought to contribute to disease progression (8) (9) (10) (11) . Interestingly, loss of dysferlin in Mo and Mp reduces adhesion and enhances cell migration and phagocytosis (9, 12 ). An aggressive Mo/Mp response may exacerbate muscle damage initiated by loss of dysferlin in muscle fibers and thus promote disease progression. Therefore, targeting the inflammatory response, and Mp in particular, may provide an avenue to ameliorate disease progression in dysferlinopathy.
In dysferlinopathy, thrombospondin-1 (TSP-1) accumulates in skeletal muscle of humans and mice and is correlated with Mp activity and disease progression in mice (13, 14) . Importantly, TSP-1 was observed in biopsies from dysferlindeficient patients but not in patients with other myopathies (13) . Although muscle cells are known to produce TSP-1 (13) , platelets and Mo/Mp also produce TSP-1 during injury and inflammation (15) (16) (17) . Functionally, TSP-1 is known to be antiangiogenic, which could be detrimental to muscle regeneration (18, 19) . In addition, TSP-1 induces chemotaxis of Mo/Mp (13, 20) , promotes phagocytosis (21, 22) and induces a pro-inflammatory Mp phenotype (19, 21, 23) . Importantly, deletion of TSP-1 was shown to improve muscle recovery following hindlimb ischemia, in part by ameliorating the Mp response (19) . Our guiding hypothesis is that TSP-1 promotes disease progression in dysferlinopathy at least in part by inducing a destructive Mp response.
The purpose of this study was to determine whether TSP-1 regulates Mp activity and disease progression in dysferlinopathy. To this end, we assessed levels of TSP-1 in dysferlinopathy patients, performed in vitro studies to elucidate the mechanisms by which TSP-1 regulates Mp function, and measured Mp activity and disease progression in dysferlin-deficient BlaJ mice crossed with TSP-1 knockout mice.
Results

TSP-1 and disease severity in dysferlinopathy patients
A previous study showed that TSP-1 accumulates in affected muscles of dysferlinopathy patients but not in muscle of patients with other myopathies (13) . To determine whether TSP-1 correlates with disease progression in dysferlinopathy patients, we measured TSP-1 levels in blood of patients and healthy age-and gender-matched controls. TSP-1 levels were higher in nonambulant patients compared with ambulant patients and healthy controls (Fig. 1) . In addition, TSP-1 levels in patients showed a significant positive correlation with age ( Fig. 1 ), but did not appear to correlate with gender or presence of diabetes or hypertension (not shown). Interestingly, TSP-1 levels were also positively correlated with age in healthy controls ( Fig. 1 ) and thus part of the increase in TSP-1 levels in non-ambulant dysferlinopathy patients may be attributed simply to the aging process. However, even when focusing on ages 40 years and older, dysferlinopathy patients had higher blood TSP-1 levels than healthy controls. Thus, similar to what we found previously in mice (14) , TSP-1 levels in blood appear to correlate with disease progression in human dysferlinopathy patients.
Loss of TSP-1 and loss of muscle volume and mass
We previously reported that psoas muscle exhibits severe loss of mass and cross-sectional area in BlaJ mice that are inversely correlated with TSP-1 levels (14) . In the present study, we measured muscle volume in MRI images as well as muscle mass and found that the psoas muscle exhibited severe losses, whereas the gluteal muscle show more moderate losses, in both parameters between 3 and 12 months of age ( Fig. 2 and Supplementary Material, Fig. S2 ). However, mice of all TSP-1 genotypes showed similar losses in volume and mass of the psoas muscle, indicating that loss of TSP-1 does not ameliorate loss of psoas muscle tissue in BlaJ mice ( Fig. 2B and C) . In contrast, mice that were heterozygous or null for TSP-1 exhibited partial sparing of gluteal muscle mass and volume compared with TSP-1 competent littermates at 9 and 12 months of age ( Fig. 2B and C) . Thus, loss of TSP-1 appears to protect against reductions in mass and volume of the moderately affected gluteal muscle, but not of the more severely affected psoas muscle.
When male and female mice were analysed separately, both genders exhibited similar overall reductions in muscle volume and mass over the time course examined for the psoas and gluteal muscles (Supplementary Material, Fig. S3 ). In addition, no differences were observed between TSP-1 genotypes for losses in volume or mass of the psoas muscle for either male or female mice (Supplementary Material, Fig. S3 ). In contrast, both genders showed some evidence of sparing of gluteal muscle with loss of TSP-1 -with females but not males exhibiting significant sparing of gluteal muscle volume, and males but not females exhibiting significant sparing of gluteal muscle mass (Supplementary Material, Fig. S3 ). Therefore, loss of TSP-1 ameliorated reductions in volume and mass of the moderately affected gluteal muscle but not in the severely affected psoas muscle. Even for the gluteal muscles, the sparing effect was modest and likely influenced by gender-dependent mechanism(s).
Loss of TSP-1 and MRI markers of inflammation
To determine the effects of TSP-1 deletion on inflammation in affected muscles over the time course of disease progression in BlaJ mice, we measured the mean pixel intensity and pixel intensity variability of T2-weighted volumetric MRI images, which may reflect edema/inflammation (14) . Both the psoas and gluteal muscles showed increasing mean pixel intensity and pixel variability with age, indicating increasing inflammation ( Fig. 2D and E and Supplementary Material, Fig. S2 ). Male TSP-1 null mice exhibited evidence of reduction in inflammation in the gluteal muscle, with decreased T2 pixel variability at 9 and 12 months of age (Fig. 2E ) associated with lower maximum T2 pixel intensity (data not shown). However, this reduction was not reflected in significantly reduced T2 mean pixel intensity. Female mice showed overall greater increases in T2 signal intensity and variability with age than male mice, with TSP-1 heterozygous female mice showing a striking large increase ( Fig. 2D and E and Supplementary Material, Fig. S2 ), indicating that female mice, particularly TSP-1 heterozygous mice, had increased muscle inflammation. Thus, the muscle mass sparing effect induced by loss of TSP-1 in males is associated with decrease in inflammation-evidence of reduced disease progression, whereas loss of TSP-1 failed to inhibit disease progression in female mice that exhibit a higher inflammatory response.
Loss of TSP and muscle fiber infiltration and regeneration in BlaJ mice
To assess the effects of TSP-1 deletion on pathology at the microscopic level, we measured the percentage of muscle fibers infiltrated by inflammatory cells and the percentage of regenerating fibers along with their diameter in hematoxylin and eosin-stained cryosections. In male mice, loss of TSP-1 significantly reduced the percentage of infiltrated fibers in both the psoas and gluteal muscles of 6-month-old mice; this reduction was not evident at 12 months mice, indicating a transient response (Fig. 3) . In female mice, we did not find any significant effect of TSP-1 genotype on these parameters (Supplementary Material, Fig. S4 ). In addition, there was no significant influence of TSP-1 genotype on regenerating fiber diameter in either gender (Supplementary Material, Fig. S4 ). Thus, loss of TSP-1 produces a transient improvement in muscle histopathology that is evident at 6 but not 12 months of age, which may contribute to the sparing of mass and reduction of pathology in MRI scans of the gluteal muscle. In addition, these effects were evident in male but not female mice.
Loss of TSP1 and macrophage accumulation in muscles of BlaJ mice
We recently reported that Mp are the predominant myeloid cell throughout disease progression in psoas and gluteal muscles of BlaJ mice (24) . To determine whether deleting TSP-1 reduces Mp accumulation in affected muscles of BlaJ mice, we measured numbers of Ly6Chi Mo, Ly6Chi Mp and Ly6Clo Mp by flow cytometry (Fig. 4A) . In a preliminary experiment, we verified that accumulation of Ly6Clo Mp was $10-fold greater than that of Ly6Chi Mo in both the psoas and gluteal muscles of BlaJ mice at 6 months of age, and that WT mice exhibit very little Mo or Mp accumulation, as we reported previously (Supplementary Material, Fig. S5 and Ref. 14) . Similar results were observed in our BlaJ mice cross-bred with TSP-1 knockout mice; Ly6Clo Mp were the most abundant CD45þ cell present (Fig. 4) .
Loss of TSP-1 reduced the number of Ly6Clo Mp in the psoas and gluteal muscles of 6-month-old male but not female mice ( Additionally, in vivo phagocytosis was assessed by intravascular injection of fluorescent-labeled iron oxide nanoparticles and measuring their uptake into muscle Mp by flow cytometry during active disease progression at 6 months of age. Again, in a preliminary experiment, we verified data from our previous study that in vivo phagocytosis is increased in Mp that accumulate in muscle of BlaJ compared with those in WT mice 
TSP-1 and macrophage pro-inflammatory gene expression and phagocytosis in vitro
Previous in vitro studies have shown that TSP-1 induces chemotaxis of Mo/Mp (13, 20) , promotes phagocytosis (21, 22) and induces a pro-inflammatory Mp phenotype (19, 21, 23) . However, these previous studies used supraphysiological concentrations of TSP-1 (14) . We sought to determine whether physiological levels of TSP-1 induced pro-inflammatory gene expression and phagocytosis in BlaJ Mp and to identify the receptors that mediate such activity. TSP-1 produced a dose-dependent increase in the expression of the pro-inflammatory cytokines IL-1b, TNF-a and IL-6 in cultured bone marrow-derived Mp derived from both WT and BlaJ mice (Fig. 5) . However, BlaJ Mp were more sensitive to TSP-1, showing elevated cytokine expression at low doses of TSP-1 that did not influence WT Mp. We also used blocking antibodies against CD36 and CD47 to determine whether TSP-1 induces cytokine expression through either of these wellstudied TSP-1 receptors (18) . Whereas the CD36 blocking antibody did not significantly alter TSP-1-induced cytokine expression compared with isotype control, the CD47 blocking antibody partially blocked TSP-1-induced IL-1b and TNF-a expression but not IL-6 expression (Fig. 5) . These data indicate a role for CD47 in the signal transduction pathway for TSP-1-induced cytokine expression in BlaJ Mp.
Furthermore and consistent with a previous report (9), unstimulated BlaJ Mp showed increased phagocytic activity compared WT Mp (Fig. 5) . TSP-1 induced a dose-dependent increase in phagocytosis in both WT and BlaJ Mp, with no difference in this TSP-1-induced phagocytosis at any concentration tested. We again used blocking antibodies against CD36 and CD47 as both of these receptors have been reported to play roles in phagocytosis (25, 26) . Whereas the CD47 blocking antibody did not significantly alter TSP-1-induced phagocytosis compared with isotype control, the CD36 blocking antibody partially blocked this effect (Fig. 5) . Thus, TSP-1-induced effects on cytokine expression and phagocytosis appear to be mediated by different receptors.
Discussion
Dysferlinopathy is associated with a potent inflammatory response dominated by Mp activity that has been implicated in the pathogenesis of the disease (8) (9) (10) (11) . Another distinguishing characteristic of dysferlinopathy is the accumulation of TSP-1 in affected skeletal muscles, which may help to drive the inflammatory response (13) . Our previous study demonstrated a correlation between TSP-1 levels and disease progression in BlaJ mice (14) , which led us to the hypothesis that TSP-1 promotes a destructive pro-inflammatory Mp phenotype that contributes to disease progression in dysferlinopathy. In the current study, we report that blood TSP-1 levels are elevated in non-ambulant dysferlinopathy patients compared with ambulant patients and healthy controls and show that TSP-1 promotes proinflammatory gene expression and phagocytic activity of BlaJ Mp in vitro. However, loss of TSP-1 in BlaJ mice did not ameliorate progressive muscle deterioration of the severely affected psoas muscle assessed by MRI markers of muscle inflammation or loss of muscle volume and mass, even though Mp infiltration in this muscle was reduced by loss of TSP-1 assessed by flow cytometry and histological analysis. Loss of TSP-1 did induce some amelioration of disease progression of the more moderately affected gluteal muscle in less inflammatory (based on MRI markers) male mice. Although a transient reduction in inflammatory cell infiltration of muscle fibers may contribute to sparing of gluteal muscle volume and mass, we conclude that while TSP-1 modulates inflammation, it does not appear to be a primary driver of disease progression in BlaJ mice. Male and female BlaJ mice responded differently to loss of one or two alleles of TSP-1, with male but not female TSP-1 null mice showing transient reductions in Mp activity and female but not male TSP-1 heterozygous mice showing the highest levels of muscle inflammation. The immunology literature may provide some clues for explaining these gender differences, as differences in both the innate and adaptive immune responses are associated with a higher prevalence of a number of autoimmune diseases in females, including rheumatoid arthritis and multiple sclerosis (27, 28) . Gender differences in immune responses may also explain the lower burden of bacterial, viral and parasitic infections in females, most evident during their reproductive years (29) . Although the underlying mechanisms for these gender differences are still being elucidated, differences in sex hormones, X chromosome gene contributions, and the effects of environmental factors may all play roles. Related to our study, gender-associated hormonal and/or genetic factors may alter bioavailability of TSP-1 and/or its downstream signaling. Indeed, TSP-1 levels have been found to be higher in females compared with males in a proteomic analysis of human patellar tendon (30) . In addition, a search of the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database revealed that a TSP-1 interacting protein, melanoma antigen family D2, is encoded in the X chromosome and can escape from X-chromosome inactivation (31), which could influence TSP-1 bioactivity in females. Whether these mechanisms are involved in gender differences in response to TSP-1 in the present study awaits further investigation. Previous studies have implicated TSP-1 in physiological and pathological processes as diverse as cancer, limb ischemia, aneurysm, pneumonia, nephritis and wound healing (18, 26) . TSP-1 likely influences these processes through its ability to influence the adhesion, migration, proliferation and differentiation of multiple cell types, including endothelial cells, fibroblasts, muscle cells and inflammatory cells. In some cases, TSP-1 appears to be protective as loss of TSP-1 in mice induces lung inflammation (32), impairs skin wound healing (33), accelerates atherosclerotic plaque maturation (34) , prolongs inflammation and expands the remodeling zone after myocardial infarct (35) and enhances inflammation and damage in a model of inflammatory bowel disease (36) . However, in other situations, TSP-1 appears to exacerbate disease as loss of TSP-1 reduces Mp infiltration and expansion of experimentally induced abdominal aortic aneurysm (37) , reduces Mp accumulation and disease progression in a mouse model of glomerulonephritis (38) , and reduces proinflammatory Mp phenotype and muscle tissue necrosis in a mouse model of hindlimb ischemia (19) . The divergent effects of TSP-1 deficiency in different diseases along with the gender, age and muscle-dependent effects observed in the present study indicate that whether TSP-1 plays a protective or destructive role likely depends on specific, but as yet undefined, characteristics of each disease process and the multi-functional effects that TSP-1 can exert on diverse cell types (18, 26) .
In addition to the modulatory effects of TSP-1, many other pathways may influence Mp activity and disease progression in dysferlinopathy. Damage-associated molecular patterns (DAMPs), including include heat shock proteins, ATP, RNA, DNA, high mobility group box 1, oxidized lipids and proteins and cytokines such as IL-1a and IL-33 (39), released from damaged muscle fibers likely contribute to these processes in part via Toll receptor-and inflammasome-mediated signaling (40) . The reduction in Mp accumulation in dysferlinopathic psoas muscle in 12-month-old BlaJ mice observed both in the present study (Fig. 3 ) and in our previous study (14) may reflect loss of DAMP production associated with the reduction in muscle tissue observed at this age. The role of DAMPs in mediating inflammation and muscle pathology in dysferlinopathy awaits further study.
A wide spectrum of Mp phenotypes are likely expressed during tissue repair/regeneration induced both by the changing microenvironment of the healing tissue as well as epigenetic programming that induces biases towards certain phenotypes (41) (42) (43) . Our in vitro studies indicated that TSP-1 may be a component of the microenvironment that induces a proinflammatory, phagocytic phenotype in BlaJ Mp (Fig. 2) . Although we did not assess expression of pro-inflammatory mediators in Mp that accumulated in damaged BlaJ muscle, our present and past data (14) demonstrate that the primary population of Mp that accumulates are F4/80þ/Ly6Clo, and this population is likely the proliferating resident Mp population recently reported by another group to be pro-inflammatory (44) . Whether the loss of TSP-1 changes the phenotype of this population of Mp in dysferlinopathic muscle remains to be determined.
Our data may be consistent with the conclusion of a previous study that Mp activity is secondary to myogenic changes associated with the disease (45) . This previous study evaluated the progression of muscle fiber damage and inflammation after For each graph, data generated from three replicates in each of three separate experiments (N ¼ 9 total). *mean value for BlaJ significantly different from that for WT control at same TSP-1 concentration or mean value significantly different from isotype control for blocking antibody studies, P < 0.05. a single bout of large strain-induced injury of the tibialis anterior muscle in 14-18-week-old male A/J mice and found that muscle fiber damage was initiated before the inflammatory response and that depletion of Mp using clodronate liposomes did not significantly affect the injury or recovery responses (45) . In our study, although we found that loss of TSP-1 reduced Mp accumulation and muscle fiber infiltration in the psoas muscle of 6-month-old male mice, this did not blunt the loss of muscle mass observed in 9-and 12-month-old mice, indicating that Mp do not likely play a role in the loss of psoas muscle mass in BlaJ mice.
Limitations of the study include a lack of statistical power to fully elucidate gender-specific effects of loss of TSP-1 on the measures of inflammation and disease progression used in this study. Despite the recent focus of the NIH on including both male and female genders in research studies, few data exist in the literature that directly compares disease progression in dysferlinopathy in both genders. In our review of the literature, a surprising number of studies did not report the gender of the mice. Most of the studies that report gender utilize only a single gender, and the studies that report using both male and female genders did not provide a comparison of results between genders. Thus, although our study is not powered to provide definitive comparisons between genders, the data do provide novel insight into gender differences in the inflammatory response and disease progression in dysferlinopathic mice.
In summary, we found that blood TSP-1 levels are elevated in non-ambulant dysferlinopathy patients compared with ambulant patients and healthy control participants, supporting our previous findings that TSP-1 levels are correlated with disease progression (14) . Deletion of TSP-1 in BlaJ mice resulted in a transient reduction in Mp accumulation, phagocytic activity and muscle fiber infiltration in psoas and gluteal muscles of male but not female mice. Despite these findings, loss of TSP-1 in BlaJ mice had little effect on disease progression in the psoas muscle, which exhibits severe disease, but did induce sparing of volume and mass in the gluteal muscle, which exhibits a more moderate disease phenotype. Thus, TSP-1 appears to play an accessory role in modulating Mp activity and disease progression in BlaJ mice in a gender, age and muscle-dependent manner.
Materials and Methods
Human participants
A total of 50 patients with confirmed dysferlinopathy were enrolled between April 2014 and January 2015 throughout the United States of America. Of these, 25 had advanced disease (non-ambulatory, average age 33.1 years and 48% male) and 25 were highly ambulatory (average age of 48.8 year and 44% male). A control group of 25 healthy participants were enrolled in Vancouver, Canada, chosen to reflect similar marginal age and sex distributions to the dysferlinopathy participants (average age of 37.2 years and 40% male). The human study was approved by the Providence Health Care Research Ethics Board and procedures involving human subjects were in accordance with the Helsinki Declaration.
Multiple reaction monitoring (MRM) assay for TSP-1 in human plasma TSP-1 was part of a panel of 60 proteins that were used for targeted peptide-based quantitation in plasma of the patients and controls of this study using LC-MRM mass spectrometry. A detailed protocol is provided in the Supplementary Material. 
Nanoparticle administration
Superparamagnetic iron oxide (SPIO) nanoparticles were used to detect Mp phagocytosis in psoas and gluteal muscles (14) . First, we conjugated SPIO nanoparticles to fluorescent tags. VivoTag 680 XL Fluorochrome (46)(PerkinElmer) was dissolved in DMSO and added to nanomag-CLD-SPIO-NH2 nanoparticles (Micromod) suspended in water. After adding 0.25 M sodium citrate and di-isopropyl ethylamine, the suspension was incubated at room temperature for 2 h while shaking. Labeled nanoparticles were separated from unconjugated label using PD-10 columns (GE Healthcare) and stored at 4 C. To minimize variability, all mice for a given time point were administered nanoparticles and uptake was analysed in the same experimental sessions. Approximately 0.5 mg of SPIO was injected intravenously via the retroorbital cavity 36 h prior to tissue harvest. To assess consistency of nanoparticle availability in vivo, we assessed uptake into liver Mp and found no qualitative differences between mice within or between time points.
Magnetic resonance imaging
Mice were subjected to MRI scanning in an Agilent 9.4 Tesla MRI system equipped with a birdcage quadrature coil. Care was taken to ensure that each mouse was scanned in the same body position. Mice were anesthetized with 1-2% isoflurane and were kept at 37C . Thirty 1-mm thick coronal slices were acquired 
Tissue collection
Tissue was harvested at indicated time points. While anesthetized, mice were subjected to systemic perfusion with PBS, the right psoas and gluteal muscles were carefully dissected and processed for muscle cell isolation. The lower trunk with left psoas muscles attached was fixed in 4% paraformaldehyde for 2 h, after which the muscles were harvested, dehydrated in sucrose embedded in tissue freezing compound and frozen in 2-methylbutane cooled on dry ice.
Muscle cell isolation
Psoas and gluteal muscles were subjected to enzymatic digestion and cells isolated as described (24) . Total nucleated cells were counted and stained with antibodies for flow cytometry analysis.
Flow cytometry
Cells isolated from blood or muscle were identified using flow cytometry. First, Fcc receptors were blocked with anti-mouse CD16/CD32 (Biolegend), then extracellular antigens were labeled with the following antibodies: Ly6G-BV421 (1A8, BD Biosciences), CD115-PE (AF598, Biolegend), Ly6C-PerCP-Cy5.5 (AL-21, BD Biosciences), CD29-pacific blue (Biolegend), CD36-FITC (Biolegend), CD47-PE (Milap301, Biolegend), CD45-FITC (30-F11, BD Biosciences), F4/80-PE (C1: A3-1, Biolegend), Ly6G-PE-CF594 (1A8, BD Biosciences), CD11b-APC/eFluor780 (M1/70, eBioscience), DAPI (Sigma-Aldrich) or with non-specific isotype controls. Samples were fixed with 0.5% paraformaldehyde and were analysed using a BD Fortessa cytometer (Becton and Dickinson). Data were analysed using FlowJo software (TreeStar).
Histology
Cryosections (10lm) from the mid-belly of the psoas muscle were stained by hematoxylin and eosin for morphological analysis or immunohistochemistry for Mp. Muscle fiber damage and regeneration was quantified on five representative images of each muscle section obtained using a 40x objective on an Eclipse 80i microscope with DS-Fi1 camera and NIS-Elements BR software (Nikon, Melville, NY). Infiltrated fibers were identified as those clearly containing multiple nuclei with morphological evidence of disruption. Regenerating fibers were identified as those containing peripherally located nuclei without evidence of damage and the minimum diameter of these fibers was measured.
Data analysis
Values are reported as means 6 standard error. Data were compared across human participant groups, across in vitro experimental conditions or across mouse genotypes using one-way analysis of variance. For mouse studies, the primary analysis was performed on data from genders combined. Because gender differences became apparent during the study, secondary analysis was performed on the genders separated. The StudentNewman-Keuls test was used for post-hoc analysis. The 0.05 level was taken to indicate statistical significance.
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Supplementary Material is available at HMG online.
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